7 September 2020 - In what appears to be a new process, the SMC has accepted three new technologies for interim use subject to their on-going evaluation and future reassessment.

The three technologies are:

• Andexanet alfa (Ondexxya) to stop life-threatening or uncontrolled bleeding in adults taking certain medicines used to thin the blood
• Polatuzumab (Polivy) to treat a type of lymphoma in patients who are unsuitable for a stem cell transplant
• Holoclar, a stem-cell treatment used to replace damaged cells in the eye after chemical or physical burns

Further information can be found on the SMC interim acceptance webpage.

Read SMC press release